Vesencumab is under investigation in clinical trial NCT00747734 (A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Vesencumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Vesencumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Vesencumab. |
| Estrone | Estrone may increase the thrombogenic activities of Vesencumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Vesencumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Vesencumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Vesencumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Vesencumab. |
| Estriol | Estriol may increase the thrombogenic activities of Vesencumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Vesencumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Vesencumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Vesencumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Vesencumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Vesencumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Vesencumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Vesencumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Vesencumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Vesencumab. |
| Equol | Equol may increase the thrombogenic activities of Vesencumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Vesencumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Vesencumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Vesencumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Vesencumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Vesencumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Vesencumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Vesencumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Vesencumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Vesencumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Vesencumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Vesencumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Vesencumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Vesencumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Vesencumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Vesencumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Vesencumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vesencumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Vesencumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Vesencumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Vesencumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Vesencumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Vesencumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Vesencumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Vesencumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vesencumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Vesencumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vesencumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Vesencumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Vesencumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vesencumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Vesencumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Vesencumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Vesencumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vesencumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Vesencumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Vesencumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Vesencumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Vesencumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Vesencumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Vesencumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Vesencumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Vesencumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Vesencumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Vesencumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Vesencumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Vesencumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Vesencumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Vesencumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Vesencumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Vesencumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Vesencumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Vesencumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Vesencumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Vesencumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Vesencumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Vesencumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Vesencumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Vesencumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Vesencumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Vesencumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Vesencumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Vesencumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Vesencumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Vesencumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Vesencumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Vesencumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Vesencumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Vesencumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Vesencumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Vesencumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Vesencumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Vesencumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Vesencumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Vesencumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Vesencumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Vesencumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Vesencumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Vesencumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Vesencumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Vesencumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Vesencumab. |